MedTrace Logo

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

NCT07074002 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-16

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drug BP1.4979 works to treat essential tremors in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are:

* Does the drug BP1.4979 reduce tremors in individuals with essential tremor?
* Do participants have a good safety and tolerability of drug BP1.4979?

Researchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat essential tremors.

Participants will:

* Take the study drug (active or a placebo) twice daily over a 4-week period
* Visit the clinic 5 times for health checkups and questionnaires completion over a period of approximately 7 to 10 weeks
* Complete a diary weekly to assess the impact of essential tremor on daily life

Conditions

Interventions

DRUG

BP1.4979

Selective dopamine D3 partial agonist

DRUG

Placebo

Matching placebo of BP1.4979 tablet

Sponsors & Collaborators

Principal Investigators

  • David Devos Coordinating Investigator, Pr · CHU de Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074002 on ClinicalTrials.gov